Patents by Inventor Jefferson Wright Tilley
Jefferson Wright Tilley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9023986Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.Type: GrantFiled: October 17, 2011Date of Patent: May 5, 2015Assignee: Hoffmann-La Roche Inc.Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
-
Patent number: 9000044Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.Type: GrantFiled: February 14, 2013Date of Patent: April 7, 2015Assignee: Hoffmann-La Roche Inc.Inventors: Fariborz Firooznia, Tai-An Lin, Eric Mertz, Sung-Sau So, Achyutharao Sidduri, Jefferson Wright Tilley
-
Patent number: 8691993Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.Type: GrantFiled: December 6, 2012Date of Patent: April 8, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Fariborz Firooznia, Tai-An Lin, Eric Mertz, Achyutharao Sidduri, Sung-Sau So, Jefferson Wright Tilley
-
Patent number: 8344027Abstract: This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.Type: GrantFiled: April 28, 2009Date of Patent: January 1, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Gerald Lewis Kaplan, Patrizio Mattei, Jefferson Wright Tilley
-
Publication number: 20120289554Abstract: This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.Type: ApplicationFiled: July 24, 2012Publication date: November 15, 2012Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Gerald Lewis Kaplan, Patrizio Mattei, Jefferson Wright Tilley
-
Patent number: 8299023Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2??(I) (SEQ ID NO: 1), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.Type: GrantFiled: August 25, 2009Date of Patent: October 30, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Waleed Danho, David Charles Fry, Robert Alan Goodnow, Jr., Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
-
Patent number: 8268784Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.Type: GrantFiled: August 6, 2009Date of Patent: September 18, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
-
Patent number: 8258134Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: GrantFiled: March 9, 2009Date of Patent: September 4, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
-
Patent number: 8222416Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: GrantFiled: November 10, 2010Date of Patent: July 17, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, Li Chen, Wendy Lea Corbett, Lichun Feng, Nancy-Ellen Haynes, Robert Francis Kester, Sung-Sau So, Jefferson Wright Tilley
-
Patent number: 8188098Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: GrantFiled: May 1, 2009Date of Patent: May 29, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Shawn David Erickson, Paul Gillespie, Kevin Richard Guertin, Prabha Saba Karnachi, Kyungjin Kim, Chun Ma, Warren William McComas, Sherrie Lynn Pietranico-Cole, Lida Qi, Jefferson Wright Tilley, Qiang Zhang
-
Publication number: 20120101037Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.Type: ApplicationFiled: October 17, 2011Publication date: April 26, 2012Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
-
Patent number: 8093253Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.Type: GrantFiled: February 23, 2009Date of Patent: January 10, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Romyr Dominique, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Jianping Lou, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
-
Patent number: 8088936Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.Type: GrantFiled: March 10, 2010Date of Patent: January 3, 2012Assignee: Hoffman-La Roche Inc.Inventors: Romyr Dominique, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
-
Patent number: 8076334Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.Type: GrantFiled: September 2, 2008Date of Patent: December 13, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Nancy-Ellen Haynes, Nathan Scott, Jefferson Wright Tilley
-
Patent number: 7989454Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.Type: GrantFiled: December 2, 2008Date of Patent: August 2, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Romyr Dominique, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
-
Publication number: 20110172147Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.Type: ApplicationFiled: March 25, 2011Publication date: July 14, 2011Inventors: Karin Conde-Knape, Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Jefferson Wright Tilley
-
Publication number: 20110144105Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: ApplicationFiled: November 10, 2010Publication date: June 16, 2011Inventors: Steven Joseph Berthel, Li Chen, Wendy Lea Corbett, LiChun Feng, Nancy-Ellen Haynes, Robert Francis Kester, Sung-Sau So, Jefferson Wright Tilley
-
Patent number: 7947692Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.Type: GrantFiled: May 11, 2007Date of Patent: May 24, 2011Assignee: Hoffmann-La Roche Inc.Inventors: John A. Brinkman, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Nicholas Marcopulos, Lida Qi, Jagdish Kumar Racha, Ramakanth Sarabu, Jenny Tan, Jefferson Wright Tilley
-
Publication number: 20110021570Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.Type: ApplicationFiled: June 16, 2010Publication date: January 27, 2011Inventors: Nancy-Ellen Haynes, Nathan Robert Scott, Jefferson Wright Tilley
-
Patent number: RE46024Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.Type: GrantFiled: July 1, 2015Date of Patent: June 7, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Nancy-Ellen Haynes, Denis J. Kertesz, Sherrie Lynn Pietranico-Cole, Yimin Qian, Nathan Robert Scott, Sung-Sau So, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley